Info on the NovaLung company and their lung products

Info on the NovaLung company and their lung products

Novalung GmbH locations

Highly qualified precision production processes in medtech manufacturing

Downloads

Solutions for Lung Failure

 Novalung‘s mission is to create new solutions for the treatment of lung failure with innovative artificial lungs that “breathe” outside the patient’s body. The pioneering task is to work with leading clinicians around the world to develop new therapies to replace damaging invasive mechanical ventilation.

Novalung GmbH was founded in Hechingen (Baden-Württemberg, Germany) in 2003 through the fusion of leading German and American technologies in the field of artificial lungs and is now active throughout the world. From the outset Novalung has focused on high-quality development and production “Made in Germany“.  Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.

click to the NovaLung web site on lungs

A artificial lung in humans ??

First experience with a paracorporeal artificial lung in humans.

Camboni D, Philipp A, Arlt M, Pfeiffer M, Hilker M, Schmid C.

Source

Departments of Cardiothoracic Surgery, University Hospital Regensburg, Germany. dcamboni@arcor.de

Abstract

Lung transplantation is the only treatment option for patients suffering form end-stage respiratory failure. To date, no mechanical device is available to support patients on the waiting list up to months. Here, we summarize our experience with our first two patients, who were supported with a paracorporeal artificial lung (PAL) placed in parallel to the pulmonary circulation with connection to the pulmonary artery and to the left atrium. A low resistance membrane oxygenator (iLA, Novalung, Hirrlingen, Germany) was attached in both patients. Our first patient suffering from a pulmonary veno-occlusive disease was supported for 18 days until he died due to severe sepsis. Our second patient with a primary pulmonary hypertension of unknown origin was supported 62 days followed by successful lung transplantation.
 In conclusion, the experience obtained with these first two patients under PAL encourages further studies and introduction of this promising concept into clinical practice.

PMID: 19282751 [PubMed - indexed

click to see lung more info at ncbi nlm.nih.gov

U.S. COPD Coalition's Semi-Annual Business Meeting

Artificial Lung amrket expands due to innovations

Innovation Expands Artificial Lung Market

Medtech Insight -- Advances in extracorporeal lung support devices are expanding the market for artificial lungs and are helping to extend and save the lives of patients with acute and chronic pulmonary disease.

 At the Society of Thoracic Surgeons' annual meeting held in San Diego in January, researchers discussed new low-flow percutaneous catheters, advances in low-resistance membrane oxygenators, and improvements in pump designs that are enabling simpler, less invasive, and more portable solutions for treating patients with respiratory failure.

click to see more info on artifical lungs

By Anne Staylor, Medtech Insight 4/1/2011

Lanka opens research, manufacturing unit for respiratory care

 Lanka opens research, manufacturing unit for respiratory care


Akbar Pharmaceuticals, for the first time in Sri Lank inaugurated a fully equipped formulation development and manufacturing facility for respiratory care.

 "Considerable investment in equipment has resulted in a state of the art facility. Among many expensive research and testing equipment installed at the ‘LINA’ formulation development and manufacturing facility for respiratory care located at Borupana Road, Ratmalana, is an artificial lung used for testing how deeply medication penetrates the lung when using inhalers and other delivery devices. A research and formulation team headed by the pioneer of development formulation for respiratory care Dr. Anil Gunathilake handles the sophisticated equipment in a sterile, climatically controlled environment, the company said in a statement.

The unit’s focus would be to produce pharmaceuticals to highest international standards while reducing the cost burden on patients, it said.

"Given the extraordinary concessions offered in the budget of 2011 for companies undertaking research, the company believes Sri Lanka’s national policy envisions promotion of such initiatives, convinced that its stated objective of building confidence in the minds of the Sri Lankan people about the quality of products made right here in this country can be achieved before long," it said

see more at
http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=22354

gas exchange in the artificial lung

iLA Membrane Ventilator

A special hollow-fiber membrane assumes the function of pulmonary alveoli.

Effective and reliable: the iLA Membrane Ventilator® (Source: Novalung Support Registry 2008)

The iLA Membrane Ventilator® is the first artificial lung that breathes for the patient outside the body. It removes carbon dioxide outside of the lung, and is perfused by the heart like a natural organ. This relieves the patient’s lung by providing gas exchange support and reducing the workload for the breathing pump. The lung is given “Time to Heal“®.
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).

Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

How it works: effective and reliable

The iLA Membrane Ventilator® incorporates a heparin-coated hollow-fiber diffusion membrane and removes carbon dioxide effectively and reliably in a very short period of time to achieve the desired target, using low blood flows of approx. 1 L/min. This extrapulmonary ventilation can be controlled via the sweep gas flow. In cases of respiratory acidosis the pH is generally returned to normal physiological levels within a few hours. This can help protect the kidney and other organs and prevent multi-organ failure.

Easy to use and easy to care for

Positioning therapy and initial mobilization are possible with the iLA Membrane Ventilator thanks to the 360° rotating curve connectors. It is also been used for both inter-hospital and intra-hospital transport. The iLA Membrane Ventilator® was developed for temporary use in intensive-care patients and is approved in Europe for up to 29 days.

click to see the NovaLung official site

gas exchange in the artificial lung by NovaLung /Ila

Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

see moe on this new lung Ila product